The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.
Companies are developing metabolomic tests both to aid in early diagnosis of the condition and to help guide treatment in patients with metabolic imbalances.
Lineagen hopes to use PWNHealth's consumer-oriented model to expand access to its testing services for developmental delay and autism spectrum disorder.
Researchers found that diagnostic autism NGS panels offered by 21 clinical labs have very little overlap and are working to create a standardized gene list.
Moleculera claims that the five-marker panel can help identify patients whose neurological conditions may be in part due to autoimmune dysfunction.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
The company is enrolling a 1,500-subject validation study of the test, which uses metabolomics to diagnose autism and identify different patient subtypes.